Penny Stocks on the Move: SANOMEDICS INTL HLDG (OTCMKTS:SIMH), Aethlon Medical, Inc. (OTCMKTS:AEMD), Advanced Cell Technology, Inc. (OTCMKTS:ACTC), Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)

SANOMEDICS INTL HLDG (OTCMKTS:SIMH) "Sanomedics" a medical technology holding company that focuses on providing game changing products, services and ideas, announced today that it has reduced its liabilities by 8% and strengthened its balance sheet following the restructure of $1 Million, plus interest, in debt owed to TCA Global Credit Master Fund LP ("TCA").SANOMEDICS INTL HLDG (OTCMKTS:SIMH) is soaring in afternoon trade, up 37% to $.14. The stock trades in a 52-week range of $.02-4.75. The penny stock reach as high as $.17 today before tracking back to it's current price.Aethlon Medical, Inc. (OTCMKTS:AEMD) is relatively unchanged in mid afternoon trading. The stock has a market cap of 63.9 million and is trading on higher than usual volume today.Earlier this week, Aethlon Medical, Inc.(OTCMKTS:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.Advanced Cell Technology, Inc. (OTCMKTS:ACTC) is taking a beating today, down 5.14% to $7.56. The highly volatile stock is now on the lower end of its 52-week range. ACTC opened the trading session at 9.03 and moved up briefly after the bell, but then started its gradual decline over the past few hours.Earlier today Advanced Cell Technology, Inc. (OTCMKTS:ACTC) announced that Phase 1/2 clinical data published online in The Lancet demonstrate positive long-term safety results using ACT's proprietary Retinal Pigment Epithelium cells for the treatment of Stargardt's macular degeneration and dry age-related macular degeneration. The publication features data from 18 U.S.-based patients with at least six months of post-transplant follow-up.Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) despite a rough market day has surged 26% today to $.63 on its positive news. In early morning trade the stock touched an intra-day high of .67 before settling at its current price this afternoon. The company now has a market cap of 58.86 million but is still on the lower end of its 52-week range.Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV), a company located in Cambridge, MA, today announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.